ArticleMultiple sclerosis and related disorders2023

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomized, double-blind, placebo-controlled trial by Daniel S Reich et Al.

Bakht Muhammad Zurmati et al.PubMed ↗Publisher ↗

No numbers read from the abstract.